FINNENCE ▪ THE WIRE FILE
THE WIRE · № 70907
News■ Unclear/unknown
Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology
KINDNews
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZE2 RECORDS
FIRST SEEN2026-10-08 11:30 UTC
LAST UPDATE2026-10-08 11:30 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A patent allowance tied to a microcap's investment and distribution rights is early-stage optionality.
Microcap GLP-1 delivery optionality, early stage
CATALYST TO WATCH
Patent grant and product development milestones
MAIN RISK
Allowance may not convert to granted patent
FULL DISPATCH
Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights VANCOUVER, BC and LAS VEGAS, Oct. 8, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) today...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 2 TIMES · FIRST 2026-10-08 11:30 UTC · LAST 2026-10-08 11:30 UTC2026-10-08 11:30 UTCNewsHydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery TechnologyCURRENT RECORD
2026-10-08 11:30 UTCNewsVictory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Aragen Life Sciences begins Operations at OneHP, an Integrated High-potency Platform in Hyderabad, India2026-10-08 11:30 UTC
Aragen Life Sciences begins Operations at OneHP, an Integrated High-potency Platform in Hyderabad, India2026-10-08 11:30 UTC
→CORRELATIONshares Healthcare
Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting2026-10-08 11:30 UTC
Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting2026-10-08 11:30 UTC
→CORRELATIONshares Healthcare
Saol Therapeutics Announces Completion of Enrollment in Pivotal Phase III BEACON Trial of SL1002 for the Treatment of Chronic Pain Related to Osteoarthritis of the Knee2026-10-08 11:30 UTC
Saol Therapeutics Announces Completion of Enrollment in Pivotal Phase III BEACON Trial of SL1002 for the Treatment of Chronic Pain Related to Osteoarthritis of the Knee2026-10-08 11:30 UTC
→CORRELATIONshares Healthcare
Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform2026-10-08 11:30 UTC
Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform2026-10-08 11:30 UTC
→CORRELATIONshares Healthcare
Viola Davis partners with GSK to educate adults 50 and older about their shingles risk2026-10-08 11:38 UTC
Viola Davis partners with GSK to educate adults 50 and older about their shingles risk2026-10-08 11:38 UTC
→CORRELATIONshares Healthcare
Expert consensus statement highlights promise of shared medical appointments for chronic disease care2026-10-08 11:43 UTC
Expert consensus statement highlights promise of shared medical appointments for chronic disease care2026-10-08 11:43 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.